(Received for publication, August 6, 1996, and in revised form, October 21, 1996)
From the Department of Medicine/Renal Division,
¶ Department of Cell Biology and Physiology, and the
George M. O'Brien Center for Kidney and Urological
Diseases, Washington University School of Medicine,
St. Louis, Missouri 63110
During monocyte-to-macrophage differentiation, the
cellular content of vacuolar H+-ATPase (V-ATPase) increases
more than 4-fold. We have shown previously that amplified expression of
the B2 subunit of the V-ATPase occurs solely by increased
transcription, and that the 5-untranslated region of the B2 gene,
containing multiple consensus binding sites for the transcription
factors AP-2 and Sp1, is required for this expression. The present
study demonstrates that AP-2 binding sequences are essential for
increased transcription from the B2 promoter during monocyte-macrophage
differentiation and that AP-2, expressed exogenously in THP-1 and other
cells, activates transcription from the B2 promoter. In mobility shift
assays, a nuclear factor from THP-1 and U-937 cells was identified that
binds to several AP-2 response elements within the B2 promoter, but
does not react with AP-2 antibodies, and has a DNA sequence binding
affinity profile that differs from AP-2. These findings suggest that a novel AP-2-like transcription factor is responsible for V-ATPase B
subunit amplification during monocyte differentiation.
The mammalian vacuolar H+ATPase, or V-ATPase,1 is a multisubunit complex that transports protons electrogenically across the membranes of intracellular endocytic and secretory compartments in all eukaryotic cells and the plasma membrane in certain specialized cell types. Its role in acidifying organelles is required for protein transport, processing, and degradation. In the plasma membrane, the V-ATPase participates in transcellular transport of H+ and other ions and in defending cytosolic pH.
The V-ATPase is similar in structure to the F0F1-ATPases (1, 2) and is composed of two distinct macrodomains. The transmembrane domain (V0) is composed of proteolipids and other integral membrane proteins and transmits protons through the lipid bilayer (3, 4, 5, 6, 7). The cytosolic domain of the enyzme (V1) is composed of three copies each of the "A" subunit (70 kDa) and the "B" subunit (56-58 kDa), as well as a single copy of the "C" (42 kDa), "D" (33 kDa), "E" (31 kDa), and "F" (14 kDa) subunits (reviewed in Ref. 8). The A subunit contains the site of catalytic ATP-binding site (9, 10), although the B subunit likely participates in catalysis (11) and may have a regulatory role (12, 13). Two isoforms of the B subunit have been identified in mammals (14, 15, 16). They are encoded by different genes and differ in amino acid sequence at the amino and carboxyl termini, although no functional differences have yet been identified. Expression of the B1 isoform is restricted to only a few tissues; it is found at highest levels in kidney and placenta. The B2 isoform is ubiquitously expressed and is most abundant in kidney and brain.2 Cells of the monocytic lineage, including monocytes, macrophages, and osteoclasts, express V-ATPase with a B2 subunit both in intracellular compartments and on their plasma membranes (18). Macrophages express the V-ATPase on their plasma membranes to aid in intracellular pH regulation when exposed to acidic environments such as abscessed tissue (19, 20); osteoclasts employ the V-ATPase in the ruffled membrane to generate an acidic microenvironment required for bone resorption (21).
In prior studies, we showed that during monocyte-to-macrophage
differentiation the cellular content of V-ATPase subunits increases by
as much as 5-fold in native monocytes and by 3-4-fold in the monocytic
cell line THP-1 (18). Both transcriptional and post-transcriptional mechanisms of amplification were observed among the different V-ATPase
subunits examined (18). The increased expression of the B2 subunit
(approximately 3.5-fold) occurred solely by transcriptional activation.
We isolated and characterized the proximal promoter region of the B2
gene and found that the DNA in the 5-untranslated region of the gene
was required for transcriptional activation during monocyte
differentiation and that this region contained multiple binding sites
for transcription factors Sp1 and AP-2.
AP-2 was first identified as a Mr = 52,000 transcription factor (22, 23) that had unique patterns of expression in
different tissues during embryonic development (24). Isoforms of AP-2 were later identified that were products of alternative splicing of RNA
from a single gene (25, 26). Subsequently, Moser et al. (27)
isolated murine genomic and cDNA clones for a homologue of AP-2,
designated AP-2, encoded by a second gene. cDNAs from the two
genes share an overall identity of 76% at the amino acid level, with
the strongest homology in the carboxyl-terminal DNA binding/dimerization domain (85% identity, 92% similarity). Both AP-2
and the original AP-2 isolate (now designated AP-2
) bind to
the DNA consensus sequence 5
-GCCNNNGGC-3
, although many variants of
this sequence have been identified (28). The functional significance of
the isoforms is unclear; both AP-2
and AP-2
activate
transcription to an equal extent, and the patterns of expression of
both genes are highly similar.
In this report, we show that AP-2 binding sites in the promoter of the
V-ATPase B2 gene are functional in vivo and are required for
regulation of B2 expression during monocyte-to-macrophage differentiation. We identify a nuclear factor from human monocytic cell
lines that binds to AP-2 consensus binding sites but is distinct from
AP-2 and AP-2
as determined by DNA binding affinity and immunological reactivity.
Unless specified otherwise, all reagents were obtained from Sigma and were reagent grade.
Isolation and Culture of CellsTHP-1 and U-937 cells were obtained from the American Type Culture Collection, Rockville, MD, and were cultured in RPMI 1640 with 10% fetal bovine serum (Hyclone; Logan, UT), 2 mM L-glutamine, and 50 µg/ml gentamicin in a 5% CO2 incubator. THP-1 cells were induced to differentiate by addition of 160 nM tetradecanoylphorbol-13-acetate (TPA) as described previously (18, 29).
DNase I FootprintingDNase I footprinting was performed
essentially as described (18), with the exception that the noncoding
strand of probe 338 to +84 was radiolabeled.
The isolation and sequence of the B2
gene proximal promoter was described previously (18). B2 promoter
fragments were inserted at the 5 end of the luciferase reporter gene
in the vector pGL3 (Promega), with the exception of B2 fragment
317
to
52, which was subcloned into the vector pGL2 (Promega). The
317
to
124 site 1 mutant was created by using restriction enzymes to
excise a portion of the wild-type promoter containing binding site 1 and then ligating in synthetic oligonucleotides containing the mutant
site. In this manner, the core AP-2 binding sequence of site 1 was
changed from 5
-GGTCTGGCC-3
to 5
-AATATAAAA-3
. Recombinant human
AP-2
was expressed from an SV40-derived promoter in the vector pSAP2
(a kind gift of M. Tainsky, University of Texas M.D. Anderson Cancer
Center).
Transfections of THP-1 cells were
performed as described previously (18, 30). For AP-2 co-transfection
experiments, 5 µg of B2 promoter-luciferase reporter plasmid plus 2 µg of pRSVcat, a vector for expression of chloramphenicol
acetyltransferase (CAT) used to normalize luciferase activity for
transfection efficiency, were co-transfected with 0-2 µg of pSAP2.
Cloning vector pGEM-5Z was added to the DNA mixtures as needed to
equalize the DNA concentration among transfections. Forty-eight hours
after transfection, cells were harvested and prepared for luciferase
and CAT assays. The experiments using transfection and subsequent
differentiation of THP-1 cells were performed as described previously
(18). Luciferase and CAT assays were performed as described previously (18, 32).
THP-1 cells
were induced with TPA for 24 h as described above. mRNA was
isolated using the FastTrack messenger RNA isolation kit (Invitrogen;
San Diego, CA), following the manufacturer's instructions. cDNA
synthesis and subcloning into the vector Uni-ZAP were performed
using a commercially available cDNA synthesis kit (Stratagene; La
Jolla, CA). For screening of this library, 1 × 106
plaques on nitrocellulose filters (Schleicher & Schuell) were probed
with a 32P-labeled 361-base pair PstI cDNA
fragment corresponding to a region within the DNA-binding domain of
human AP-2
(spanning amino acid residues 278-399; EMBL/GenBank
accession number Y00229[GenBank]). Following hybridization of the probe, filters
were washed under final conditions of 42EC in 2 × SSPE and 0.1%
SDS. Plaques were purified through multiple rounds of screening, and
pBluescript plasmids containing the inserts of interest were excised
from the Uni-ZAP vector using ExAssist interference-resistant helper phage (Stratagene).
Nuclear extracts from dividing or differentiated THP-1 cells were prepared by the method of Dignam et al. (33), except nuclear proteins were further purified by precipitation with 55% saturated ammonium sulfate prior to dialysis. Nuclear extracts from other cell types were prepared by a modification of the method of Lee et al. (34) for small cell numbers.
For gel mobility shift assays, double-stranded oligonucleotides were
end-labeled with [-32P]ATP and T4 polynucleotide
kinase. The oligonucleotide pair containing the AP-2 binding sequence
5
-GATCGAACTGACC
CCGT-3
(core binding site
underlined) from the human metallothionein IIa distal basal level
element was purchased from Promega. The B2 promoter site 1 oligonucleotide was composed of the sequence
5
-CAAGCA
CCAGCGGCGCG-3
corresponding to
173 to
148 with respect to the start of translation. The site 5 oligonucleotide was composed of the sequences
5
-GCCTCG
CGCCTT-3
corresponding to
73 to
53.
The oligonucleotide containing the Sp1 consensus binding sequence
5
-ATTCGATCGGGGCGGGGCGAGC-3
was purchased from Promega. Purified
recombinant Sp1 and AP-2
were obtained from Promega.
Approximately 30 fmol of end-labeled oligonucleotides (5 × 104 Cerenkov counts) were mixed with 1-6 µg of nuclear
extract in a buffer containing (final concentration) 50 mM
NaCl, 10 mM Tris-HCl, pH 7.5, 1 mM
MgCl2, 0.5 mM EDTA, 0.5 mM
dithiothreitol, 4% glycerol, and 0.05 mg/ml poly(dI-dC)·(dI-dC).
Following a 20-min incubation at room temperature, DNA-protein
complexes were separated in a 4% nondenaturing acrylamide gel, which
was then dried and exposed to x-ray film. Supershift assays were
performed by incubating 1-5 µg of antibody against AP-2 (Santa
Cruz Biotechnology; Santa Cruz, CA) with nuclear extract mixtures for
2 h at 4 °C prior to addition of radiolabeled probe and gel
electrophoresis. Oligonucleotide competition reactions were performed
by preincubating the nuclear extract with unlabeled oligonucleotides
for 10 min at room temperature prior to addition of the radioactive
probe.
Data on promoter activity are presented as mean ± S.E. and were analyzed by one-way analysis of variance using SigmaStat (Jandel Scientific; San Rafael, CA). A p value of 0.05 was used as the threshold criterion for statistical significance.
In previous DNase I footprinting studies in
which the coding strand of the B2 promoter was labeled (18), we found
that the 5-untranslated region and proximal coding region of the B2
promoter contained five sequences capable of binding purified AP-2
in vitro. In the present study, we performed footprinting
experiments in which the non-coding strand was labeled. We identified
three additional potential AP-2 binding sites (Figs. 1 and
2). The five AP-2 binding sites noted previously are
designated sites 2, 5, 6, 7, and 8. Of the three newly identified AP-2
binding sequences, two (sites 3 and 4), composed of the sequence
5
-GCCGRRGCC-3
(where R indicates purine), were found embedded within
Sp1 binding sites. The most proximal site (site 1) contained a
near-perfect palindromic sequence 5
-GGTCTGGCC-3
. Purified AP-2
also bound at the G + C-rich region of transcriptional initiation,
although this site would not be expected to be active in
vivo due to interference from the basal transcription complex.
Promoter deletion studies (Fig. 3, discussed below) show
that this site does not mediate AP-2-enhanced transcription in
vivo.
Expression of Exogenous AP-2 Increases Expression from B2 Gene Promoters
To determine whether AP-2 can bind to the B2 promoter
in vivo and mediate induction of gene expression, we
co-transfected into undifferentiated THP-1 cells up to 2 µg of the
plasmid pSAP2, for exogenous expression of human AP-2 (35), with a
plasmid containing one of several B2 promoter-luciferase reporter
constructs. Five promoter constructs were used. 1) A fragment spanning
from
317 to +30 containing AP-2 binding sites 1-8; 2) fragment
317 to
52 containing AP-2 binding sites 1-5; 3) fragment
317 to
124
containing site 1 only; 4)
317 to
199, containing no AP-2 binding
sites except the sequence at the transcriptional start site; and 5)
317 to
124mut, containing a mutated AP-2 binding site 1.
The results are shown in Fig. 3. Co-transfection of pSAP2 with the
promoter constructs in THP-1 cells resulted in up to 4-fold greater
luciferase activity than in cells transfected with control plasmid. The
presence of at least one AP-2 binding site was required for this
activation, since deletion or mutation of all sites abolished the
effect of exogenous AP-2. Site 1 alone was sufficient to mediate an
increase in transcriptional activity, although the magnitude of this
increase was less than those mediated by longer constructs. For all
constructs, luciferase activity increased with the concentration of
pSAP2 in the range of 0-2 µg. With higher amounts, however, luciferase activity began to decrease (not shown), most likely due to
self-interference of AP-2 transcriptional activation as described by
Kannan et al. (35). Expression of exogenous AP-2 in the
cell lines LLC-PK1 (a porcine kidney proximal tubule line), 293 (a human embryonic kidney fibroblast line), and HepG2 (a human hepatoma line) also resulted in increased activity of the B2 promoter, but higher concentrations of pSAP-2 plasmid were required for promoter
activation in 293 and HepG2 cells (data not shown). These results
demonstrate that AP-2
is capable of activating transcription from
the V-ATPase B2 promoter in multiple cell lines.
In a prior study (18),
we showed that sequences in the region between 96 and
199,
containing three AP-2 binding sites, were required for transcriptional
activation from the B2 promoter during monocyte-to-macrophage
differentiation. To delineate further the segment of the gene required
for transcriptional activation, we performed an analysis of additional
deletions in this region. A luciferase construct was created with
promoter sequences from
274 to
124 (containing only AP-2 site 1)
and tested for the ability to enhance transcription during
monocyte-macrophage differentiation (Fig. 4). The magnitude
of activation with the
274 to
124 construct, although it did not
achieve statistical significance (p = 0.053), was less
than those mediated by longer constructs, a result similar to that
obtained by coexpression of exogenous AP-2 with this promoter fragment
(see Fig. 3). These results suggest that site 1, or surrounding sequences, accounts for at least part of the transcriptional response to a differentiation stimulus. To determine whether deletion of site 1 abolished transcriptional activation during monocyte-to-macrophage differentiation, we examined the ability of construct
317 to
124mut, containing a mutation in site 1 (see Fig. 3 and
"Experimental Procedures"), to enhance transcription during
monocyte-macrophage differentiation. In THP-1 monocytes transfected
with this construct, no increase in luciferase activity was observed
following phorbol ester treatment (Fig. 4). This indicates that AP-2
binding sites have an essential role in induction of B2 expression
during monocyte-to-macrophage differentiation.
A Monocytic Nuclear Protein Binds to AP-2 Consensus Sequences
To identify monocytic nuclear proteins capable of
binding AP-2 binding sites, we performed gel mobility shift assays
using nuclear extracts from undifferentiated or differentiated THP-1 cells. Nuclear extracts from both THP-1 monocytes and THP-1 macrophages contained a protein that bound to radiolabeled oligonucleotides containing AP-2 binding site 1 from the B2 promoter (Fig.
5A). Binding specificity was demonstrated by
addition of either unlabeled probe or an unlabeled oligonucleotide
containing a different AP-2 binding site (from the human
metallothionein IIa basal level element (28)), which abolished binding
of the nuclear proteins to the labeled probe; addition of an irrelevant
oligonucleotide, however (in this case, the binding sequence for Sp1,
another G + C-rich sequence), did not abolish binding of the proteins
to the labeled probe. The amount of site 1 oligonucleotide bound
by nuclear extract was increased in THP-1 macrophages compared with
THP-1 monocytes (Fig. 5A).
To determine if the apparent increase in the AP-2-like factor in THP-1 macrophages was due to a more efficient extract preparation, we assayed the same extracts for Sp1 binding proteins. Studies in U-937 cells, another human monocytic leukemia cell line, have shown that the Sp1 content of monocytes does not change significantly during TPA-induced differentiation into macrophages (36). We found that the Sp1 content of THP-1 cell nuclear extract preparations exhibited a minor decrease during differentiation to macrophages (Fig. 5B), suggesting that greater recovery of transcription factors was not the reason for the increase in AP-2-like factor binding. The basis for the slight decrease in the Sp1 content of THP-1 cell nuclear extract is unclear but may have caused underestimation of the increase in AP-2-like factor binding.
We next incubated THP-1 nuclear extracts, or purified AP-2, with
oligonucleotides containing different AP-2 binding sequences to
determine whether any differences in binding affinity existed among
several sequences of DNA capable of binding AP-2
(Fig. 6). The oligonucleotide probes included the following: 1) a
commercially available AP-2 binding sequence (Promega) from the human
metallothionein IIa distal basal level element (hMtIIa BLE; (28)); 2)
the B2 promoter AP-2 binding site 1; and 3) the B2 promoter AP-2
binding site 5. Fig. 6 illustrates two significant differences between the THP-1 factor and recombinant AP-2
. First, the mobility of the
THP-1 factor was consistently greater than that of AP-2
under the
assay conditions. Second, the THP-1 factor and recombinant AP-2
exhibited different relative affinities for the probes tested. The
hMtIIa BLE site oligonucleotide bound strongly to recombinant AP-2
,
forming a single protein-DNA complex. When incubated with THP-1
extracts, the hMtIIa BLE site oligonucleotide formed multiple protein-DNA complexes. In contrast, the B2 site 1 and 5 oligonucleotide probes formed a single predominant protein-DNA complex in THP-1 nuclear
extracts and bound to recombinant AP-2
weakly in comparison to the
hMtIIa probe. Quantitation of the THP-1 factor (see Fig. 7,
below) showed the concentration of this DNA-binding protein to be
several hundred-fold less than that of AP-2
in the reactions. A
second protein-DNA complex that migrated slightly ahead of the predominant complex was found occasionally in THP-1 extract
preparations in some experiments (see site 1 probe, lane 3).
This protein-DNA complex was not observed reproducibly and may
represent a degradation product of the intact transcription factor.
Although we found that site 1 bound to purified AP-2
in DNase I
footprinting assays (Fig. 1), we were unable, in repeated experiments,
to detect any protein-DNA complex formation between site 1 and purified
AP-2
in the gel mobility shift assays. We were able, however, to
inhibit completely binding of recombinant AP-2
to the hMtIIa BLE
site by preincubating the factor with a >5000-fold excess of unlabeled site 1 oligonucleotide (data not shown).
To compare the concentration of the THP-1 factor in these assays with
that of AP-2, we determined the concentration of the THP-1 factor
using the gel mobility shift assay. A constant amount of THP-1 monocyte
extract was incubated with increasing amounts of radiolabeled site 5 probe, and the amount of protein-DNA complex formed was assayed,
allowing the number of moles of probe bound to be determined when all
of the available THP-1 factor was complexed (Fig. 7A). The
intensity of the factor-DNA complex at saturation was compared with a
standard curve of free probe of known specific activity (Fig.
7B). Assuming a 1:1 molar ratio of factor to DNA in the
complex, we estimated the concentration of THP-1 monocyte factor in our
standard DNA-binding reactions (i.e. Fig. 6) to be 0.12 nM. In contrast, the concentration of recombinant AP-2
in the reactions shown in Fig. 6 was 40 nM. Thus, even at a
concentration 330-fold greater than the THP-1 factor, AP-2
bound to
the site 1 and 5 probes only weakly. Both the difference in the
affinity of AP-2
and the THP-1 factor for different probes, and the
differences in mobility of the protein-DNA complexes formed, strongly
suggest that the two proteins are distinct.
As an additional and independent method for determining whether the
THP-1 nuclear factor was different from AP-2, we analyzed the
protein-DNA complexes using the antibody "supershift" method (37)
to determine whether the factor is immunologically similar to AP-2
(Fig. 8). Antibody to the carboxyl terminus of human AP-2
(Santa Cruz Biotechnology), incubated with nuclear proteins prior to
probe addition and electrophoresis, did not produce a mobility supershift of protein-DNA complexes from THP-1 cells (from either the
monocytic or macrophage-like forms), but the antibody shifted the
mobility of the entire AP-2
-oligonucleotide complex. Although the
antibody was not tested directly in supershift assays for binding to
AP-2
, it does detect AP-2
on immunoblots and should have caused a
mobility supershift if the THP-1 factor were AP-2
(27).
To determine whether other cells of the monocytic lineage have an AP-2
site-binding protein with properties similar to the factor in THP-1
cells, we performed mobility shift and supershift assays with nuclear
extracts from the promonocytic cell line U-937 (Fig. 8). Like THP-1
cells, U-937 nuclear extracts contained a protein that formed complexes
with AP-2 consensus binding sequences, but showed a higher mobility
than AP-2 in gel mobility shift assays, and did not exhibit a
mobility supershift with the anti-AP-2
antibody. The protein-DNA
complexes from the THP-1 and U-937 nuclear extracts failed to show any
mobility supershift with addition of as much as 5 µg of anti-AP-2
antibody (not shown).
Because AP-2-like factors have not been well studied in monocytic cell
lines, we examined the possibility that THP-1 cells express novel
proteins with homology to AP-2 DNA-binding domains. A THP-1 macrophage
library was created and screened at low stringency using a cDNA
probe corresponding to the DNA-binding domain of AP-2. Three plaques
were isolated from approximately 1 × 106 screened
plaques that exhibited a positive signal through three rounds of
screening. All three recombinant phage plaques contained the same
insert, which encoded portions of the DNA binding domain and
3
-untranslated region of AP-2
(nucleotides 1184-2103 relative to
the start of transcription). Thus, THP-1 cells express AP-2
, even
though the predominant DNA-binding protein in the mobility shift assays
appeared to be a distinct factor.
To address the possibility that the monocytic factor was indeed
AP-2, but was exhibiting altered mobility and immunoreactivity due
to effects of the nuclear extract, we performed experiments in which
recombinant AP-2
was added to THP-1 nuclear extracts, and the
mixture was used to perform mobility shift and supershift assays (Fig.
9). When incubated with THP-1 nuclear extracts, AP-2
retained its original mobility and ability to react with the
anti-AP-2
antibody, whereas the monocytic factor was unaffected
(Fig. 9). These data, along with those shown in Figs. 6, 7, 8, indicate that the predominant factor in THP-1 nuclei that binds to AP-2 binding
sites in the B2 promoter is distinct from AP-2.
Leukemic cell lines of the myeloid lineage, such as THP-1, have served as excellent tools in studies of the terminal differentiation processes of hematopoietic cells (38). In this report, we have demonstrated that AP-2 binding sites are essential for amplification of V-ATPase B2 subunit transcription during macrophage differentiation. We have identified a nuclear factor in THP-1 cells that bind to these sites and whose binding activity increases following differentiation of THP-1 cells into macrophages. Our results therefore suggest that a factor related to the AP-2 family of factors is involved in gene regulation during macrophage differentiation. The predominant protein from THP-1 cell nuclear extracts forming protein-DNA complexes with AP-2 binding sites, however, is a novel factor distinct from AP-2.
Recent studies have implicated transcription factors from multiple gene
families as critical for terminal differentiation of macrophages. These
factors include members of the STAT (39) and C/EBP (40) families; Pu.1,
a member of the ets family (41); and Egr-1, a zinc finger transcription
factor (42), among others. Although the role of transcription factor
AP-2 in terminal differentiation has been elucidated in other cell
types, including neuroectodermal and epidermal cells (43, 44), the role
of AP-2 in monocytic differentiation and gene expression has been
addressed in only a few studies that have used the U-937 cell model.
AP-2 binding sites were found to be required for tumor necrosis factor
expression induced by granulocyte-macrophage colony-stimulating
factor but not by phorbol ester (45). AP-2 binding sequences were also found not to have any enhancer activity for transcription of downstream reporters during phorbol ester-induced differentiation of U-937 cells
(46). Although these findings appear to conflict with our results, we
have shown that THP-1 cells closely mimic primary blood monocytes in
their ability to express V-ATPase during differentiation, whereas U-937
cells do not (18).3 The mechanisms that cause
increased transcription of the B2 subunit in primary blood monocytes
and phorbol ester-induced THP-1 cells therefore may not be functional
in phorbol ester-treated U-937 cells. In support of this possibility,
we found that the AP-2 site-binding activity was lower in nuclear
extracts from phorbol ester-treated U-937 cells than from control U-937
promonocytes (data not shown).
The promoter of the V-ATPase B2 subunit contains eight functional AP-2
binding sites, and at least one of these sites is necessary for
increased expression from the B2 promoter during macrophage differentiation. We have not determined if site 1 is the only active
site in the B2 promoter nor if other downstream sequences are active
in vivo. Promoters containing site 1 alone (317 to
124)
showed transcriptional activity somewhat less than those containing
additional AP-2 binding sites and an Sp1 site (
317 to
96; Figs. 3
and 4), but these differences did not reach statistical significance.
Four of the AP-2 binding sites (sites 2-5) are in such close proximity
to Sp1-binding sites that interference, due to binding of Sp1, is
likely to occur. We have tested this by performing gel mobility shift
assays with an oligonucleotide probe that contains AP-2 binding sites 4 and 5 and the overlapping Sp1-binding site. When incubated with THP-1
monocyte or macrophage nuclear extracts, the only detectable
protein-DNA complexes formed were with Sp1 (data not shown). These
results suggest that Sp1 in the nuclear extracts interferes with the
binding of the THP-1 factor to AP-2 sites 4 and 5. Competition by
transcription factors for adjacent and overlapping binding sites has
been noted previously for several promoters and is a mechanism by which
the action of factors can be regulated (47, 48, 49). DNase I footprinting of promoter using the nuclear extracts will be required, however, for a
direct assessment of protein-DNA interactions in the B2 subunit
promoter.
The identity of the factor from THP-1 and U-937 cell nuclei identified
here is unknown. A probe containing the conserved DNA binding domain of
AP-2 that was used to screen a THP-1 cell cDNA library at low
stringency hybridized only to a single gene product, AP-2
itself.
Since AP-2
is expressed in these cells, it is unclear why it was not
detected in the mobility shift assays. The most likely explanation is
that the THP-1 factor binds AP-2 consensus sequences in the B2 promoter
with a higher affinity than AP-2
, as shown in Fig. 6. When mobility
shift assays were performed on THP-1 nuclear extracts using an
oligonucleotide probe that binds strongly to purified AP-2
(the
hMtIIa BLE site), several protein-DNA complexes were formed, one of
which was nearly identical in size to the complex formed with
recombinant AP-2
. In experiments using the site 1 or site 5 probes,
a barely detectable protein-DNA complex was occasionally present with
the same mobility as the AP-2
·hMtIIa BLE complex, but it was not
observed reproducibly enough to allow determination of its
identity.
Although these studies have not excluded the possibility that AP-2
has a role in B2 transcription in vivo, our experiments suggest that the THP-1 factor identified here is the predominant activator of the B2 promoter in cells of the monocytic lineage. Preliminary studies indicate that a factor similar to the one described
here is present in differentiated bone marrow and spleen cell cultures
enriched for osteoclasts (data not shown). Efforts to purify this
factor and determine its identity are in progress.
The B2 isoform of the vacuolar H+-ATPase appears to be a "housekeeping" gene product, residing in the V-ATPases that acidify the intracellular membranes of vertebrate cells (8, 16, 50). Many housekeeping genes contain G + C-rich TATA-less promoters, similar to the B2 subunit promoter. In contrast to most housekeeping genes, however, the V-ATPase B2 subunit is highly expressed in a small population of cells that are specialized for proton secretion, such as macrophages, osteoclasts, and the renal proximal tubule, in cells that maintain high rates of endocytosis and exocytosis, including macrophages and proximal tubule cells, and in cells that require V-ATPase activity for solute transport, such as neurons. AP-2-like proteins may provide a mechanism by which amplified expression of the V-ATPase may occur in specific cell types. It is perhaps not coincidental that the kidney and brain, which express high levels of B2 mRNA, also express very high levels of AP-2 proteins during development and in adulthood. Our studies may have identified a unique transcription factor, binding to AP-2 sites, that confers the capacity for cells to maintain high levels of B2 expression.
We thank Dr. Kenneth Murphy for use of the luminometer, K. Amanda Wilson for technical support, and Dr. Reinhard Buettner for helpful discussions.